Medical Xpress July 12, 2021
Scott Lafee, University of California - San Diego

Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.

The study findings could measurably change how researchers sift through big data to find meaningful information with significant benefit to patients, the pharmaceutical industry and the nation’s health care systems.

“Academic labs and pharmaceutical and biotech companies have access to unlimited amounts of ‘big data’ and better tools than ever to analyze such data. However, despite these incredible advances in technology, the success rates in discovery are lower today than in the 1970s,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma, Pharma / Biotech, Technology
Aviv Regev: The Revolution in Digital Biology
How to use LLMs to lose your competitors: A mixology for enterprise leaders
Report: Apple and OpenAI Reopen iPhone AI Talks
General Catalyst Reportedly Raises Nearly $6 Billion for Tech Firms
What do employees really want out of generative AI?

Share This Article